US expansion Lumos Diagnostics is expanding its US footprint with new office space and a major distribution agreement facilitated by an FDA waiver, indicating growing demand and potential channel partnerships to target with regional sales efforts.

Distribution partners Existing exclusive six-year distribution arrangement with Phase Scientific and recent contract manufacturing with Micro-Pak suggest multi-channel sales opportunities, co-marketing possibilities, and expanded product reach for Phase Scientific and Micro-Pak’s customer bases.

POC growth Focus on rapid, cost-effective point-of-care tests across infectious and inflammatory diseases presents a recurring demand stream for clinics and hospitals, creating cross-sell opportunities for Lumos-branded tests alongside customized assay development services.

US partnerships Strategic US partnerships for FebriDx expansion with MedPro associates indicate a validated route to accelerate adoption in the US market, suggesting targeted outreach to healthcare networks, distributors, and diagnostic laboratories.

Financial momentum Recent capital activities including a US$14m placement and ongoing funding indicate liquidity and growth readiness, enabling sales teams to pursue larger contracts, multi-year deals, and expanded manufacturing capacity discussions.